World BioProcess Leaders China Summit 2016

World BioProcess Leaders China Summit 2016

Sep 22nd to 23rd,2016

Parkyard Hotel Shanghai China

 

World BioProcess Leaders China summit provides you with practical tools, technologies and strategies to drive efficiencies in your process development and biomanufacturing activities so you can accelerate your biologics to commercialization. Benefit from multiple case studies and industry experts who will share strategies to save you time and money while reducing the development timeline from IND to market.

 

You will learn how to navigate the CMC studies and regulatory challenges of biological products developed in China and compare requirements from the CFDA and US FDA. You will also learn about new approaches for upstream and downstream development, biomanufacturing facility readiness, analytical and quality control for a wide-range of biotherapeutics including ADCs, bispecifics, next-generation mAbs and biosimilars.

 

No other conference in China provides a more comprehensive update of the technical, scientific and strategic innovations across all phases of bioprocess development.

 

With over 40 speakers and estimation to bring over 180 Biopharma professionals, the key congress topics will cover:

 

• Upstream: Cell Line and Cell Culture Processing

• Downstream: Recovery, Purification and Viral Safety/Clearance

• Navigating Regulatory Interactions with CFDA and US FDA

• Portfolio Updates on Innovative Biologics R&D in China

• Analytical Methods and Formulation Strategies and Technologies

• Quality Control, Quality Assurance and QbD

• Biomanufacturing, Facility Readiness and GMP Compliance

• Biosimilars: Regulatory Experiences and Risk-based Strategies

 

Previous and current speakers as below,

 

Audrey Jia,M.D., Ph.D, Former FDA biological product CMC Reviewer, Division of Monoclonal Antibodies, Office of Biotechnology Products,CDER, USFDA, USA

Huijun Gao,Deputy Director,Shanghai FDA

Stefan Schmidt, Ph.D., MBA, Vice President, GMP Operations, Rentschler Biotechnologie GmbH

Peter F. Moesta, Ph.D., Senior Vice President, Biologics Development & Operations, Bristol Myers Squibb Co.

Robert Friesen, Ph.D.,Vice President and Global Head of Biologics Research, Biotechnology Center of Excellence, Janssen R&D, LLC (Johnson & Johnson), USA

Rene Hoet, Ph.D.,Vice President Global Biologics, Antibody Lead Discovery,

Bayer Healthcare, Germany

Johannes Salzbrunn,Head of GMP Downstream / Fill & Finish, Boehringer Ingelheim Shanghai Pharmaceuticals, China

Satoru Noguchi,Vice President, Emerging Market Business Unit Area Head of Greater China,Chairman,Takeda (China) Holdings

Kim Wong,Director, Facilities & cGMP Support, BioProcess Research & Development,Sanofi Pasteur, Canada

James Sayer,Director, Global Product Quality,Amgen, United States

Scott Wheelwright,CEO,Complya Asia, China

Zhiwei Song,Principal Scientist, Expression Engineering, Bioprocessing Technology Institute, A*STAR, Singapore

Jong Seo Lee, CEO,AbClon, Korea

Weijun Li, Ph.D.,Senior Staff Development Scientist, Analytical Development and Support, Global Biological Development,Bayer HealthCare LLC, USA

Yanrong Dong, M.D.,Senior Scientist/Group Leader, Cell Biology,AlphaMab Co. Ltd., China

Qibin Liang,Chief Operation Officer,MabPlex International, China

Wen Ryan, Ph.D., Vice President of Technical Operations, Livzon Mabpharma, Inc., China

Wenjie Cheng, Ph.D., Principal Scientist, Process Science and Engineering, Immunogen, Inc., USA

Yunpeng Su, D.Phil., Scientific Director, NovoMab Biopharmaceutical, Inc., China

Doug Chen, Director of Process Development, Shanghai Benemae Pharmaceutical Co., China

Jian Ni, CEO, The National Engineering Research Center of Antibody Medicine (CMAB), China

Sheldon Cao, CEO, Zova Biotherapeutics Inc., China

Bruce Nian He Han, Chief Scientific Officer, NewBio Therapeutics, China

Wenzhi Tian, Founder and President, ImmuneOnco Biopharma, China

Frederic Rohmer,General Manager,Lilly Suzhou Manufacturing, China

Hang Zhou,Director of Biologics,Wuxi AppTec Biopharmaceuticals, China

Claudia Lin,Vice President of Quality and Compliance,Innovent Biologics, China

Yanshan Huang,CEO,Zhejiang Doer Biologics, China

Qing Qiao Robin Tan,Head of Analytical Science,Shanghai CP Guojian Pharmaceutical, China        

Jason Li,Vice President,Genor Biopharma, China

Xueming Qian,Chairman and CEO,MabSpace Biosciences, China

Amy Que,Executive Director, Protein Analytical Science, Biologics and Bioprocess, Wuxi AppTec

Dr Jincai Li, Executive Director, Biologics Process Development, Wuxi AppTec, China

Changlin Dou,Deputy General Manager, BoAn Biotechnology

Company, A Subsidiary of Luye Pharma Group, China

 

Contact Person:Marketing Department

Direct Line:86 21 31602153

Email:Marketing@wbfgroup.com

Website: http://www.bioprocesschina.com/